U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Levine CB, Fahrbach KR, Siderowf AD, et al. Diagnosis and Treatment of Parkinson's Disease: A Systematic Review of the Literature. Rockville (MD): Agency for Healthcare Research and Quality (US); 2003 Jun. (Evidence Reports/Technology Assessments, No. 57.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Diagnosis and Treatment of Parkinson's Disease

Diagnosis and Treatment of Parkinson's Disease: A Systematic Review of the Literature.

Show details

References

1.
Tanner C M, Golman S M. Epidemiology of Parkinson's Disease. Neurol Clin. 1996;14:317–35. [PMC free article: PMC7173037] [PubMed: 8827174]
2.
Mayeux R, Marder K, Cote L J. et al. The frequency of idiopathic Parkinson's Disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. Am J Epidemiol. 1995;142:820–7. [PubMed: 7572958]
3.
de Rijk M C, Tzourio C, Breteler M M B. et al. Prevalence of parkinsonism and Parkinson's Disease in Europe: The EUROPARKINSON collaborative study. J Neurol Neurosurg Psychiatry. 1997;62:10–5. [PMC free article: PMC486688] [PubMed: 9010393]
4.
Scheife R T, Schumock G T, Burstein A. et al. Impact of Parkinson's Disease and its pharmacologic treatment on quality of life and economic outcomes. Am J Health-Syst Pharm. 2000;57:953–62. [PubMed: 10832495]
5.
Zhang Z X, Roman G C. Worldwide occurrence of Parkinson's Disease: An updated review. Neuroepidemiology. 1993;12:195–208. [PubMed: 8272179]
6.
Louis E D, Marder K, Cote L. et al. Mortality from Parkinson Disease. Arch Neurol. 1997;54:260–4. [PubMed: 9074394]
7.
Berchou R C. Maximizing the benefit of pharmacotherapy in Parkinson's Disease. Pharmacotherapy. 2000;20:33S–42S. [PubMed: 10641990]
8.
Dodel R C, Singer M, Kohne-Volland R. et al. The economic impact of Parkinson's Disease. Pharmacoeconomics. 1998;14:299–312. [PubMed: 10186468]
9.
Agid Y, Ruberg M, Javoy-Agid F. et al. Are dopaminergic neurons selectively vulnerable to Parkinson's Disease? Adv Neurol. 1993;60:148–64. [PubMed: 8420132]
10.
Prasad K N, Cole W C, Kumar B. Multiple antioxidants in the prevention and treatment of Parkinson's Disease. J Am Coll Nutr. 1999;18:413–23. [PubMed: 10511322]
11.
Stoof J C, Winogrodzka A, van Muiswinkel F L. et al. Leads for the development of neuroprotective treatment in Parkinson's Disease and brain imaging methods for estimating treatment efficacy. Eur J Pharmacol. 1999;375:75–86. [PubMed: 10443566]
12.
Riess O, Jakes R, Kruger R. Genetic dissection of familial Parkinson's Disease. Mol Med Today. 1998;4:438–44. [PubMed: 9793932]
13.
Veldman B A, Wijn A M, Knoers N. et al. Genetic and environmental risk factors in Parkinson's Disease. Clin Neurol Neurosurg. 1998;100:15–26. [PubMed: 9637199]
14.
Williams A C, Smith M L, Waring R H. et al. Idiopathic Parkinson's Disease: A genetic and environmental model. Adv Neurol. 1999;80:215–8. [PubMed: 10410724]
15.
Racette B A, McGee-Minnich L, Moerlein S M. et al. Welding-related parkinsonism. Clinical features, treatment, and pathophysiology. Neurology. 2001;56:8–13. [PubMed: 11148228]
16.
Semchuk K K M, Love E J, Lee R G. Parkinson's Disease and exposure to agricultural work and pesticide chemicals. Neurology. 1992;42:1328–35. [PubMed: 1620342]
17.
Hellenbrand W, Seidler A, Robra B P. et al. Smoking and Parkinson's Disease: A case-control study in Germany. Int J Epidemiol. 1997;26:328–39. [PubMed: 9169168]
18.
Morens D M, Grandinetti A, Davis J W. et al. Evidence against the operation of selective mortality in explaining association between cigarette smoking and reduced occurrence of idiopathic Parkinson Disease. Am J Epidemiol. 1996;144:400–4. [PubMed: 8712197]
19.
Ross G W, Abbott R D, Petrovitch H. et al. Association of coffee and caffeine intake with the risk of Parkinson's Disease. JAMA. 2000;283:2674–9. [PubMed: 10819950]
20.
Tzourio C, Rocca W A, Breteler M M B. et al. Smoking and Parkinson's Disease: An age-dependent risk effect? Neurology. 1997;49:1267–72. [PubMed: 9371906]
21.
Shults C W, Haas R H, Beal M F. A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's Disease. Biofactors. 1999;9:267–72. [PubMed: 10416040]
22.
de Rijk M C, Breteler M M B, den Breeijen J H. et al. Dietary antioxidants and Parkinson Disease: The Rotterdam Study. Arch Neurol. 1997;54:762–5. [PubMed: 9193212]
23.
Hellenbrand W, Boeing H, Robra B P. et al. Diet and Parkinson's Disease II: A possible role for past intake of specific nutrients. Results from a self administered food-frequency questionnaire in a case-control study. Neurology. 1996;47:644–50. [PubMed: 8797457]
24.
Logroscino G, Marder K, Cote T. et al. Dietary lipids and antioxidants in Parkinson's Disease: a population-based, case-control study. Ann Neurol. 1996;39:89–94. [PubMed: 8572672]
25.
Hellenbrand W, Seidler A, Boeing H. et al. Diet and Parkinson's Disease I: A possible role for past intake of specific foods and food groups. Results from a self administered food-frequency questionnaire in a case-control study. Neurology. 1996;47:636–42. [PubMed: 8797456]
26.
Gelb D J, Oliver E, Gilman S. Diagnostic Criteria for Parkinson Disease. Arch Neurol. 1999;56:33–9. [PubMed: 9923759]
27.
Calne D B, Snow B J, Lee C. Criteria for diagnosing Parkinson's Disease. Ann Neurol. 1992;32:S125–7. [PubMed: 1510370]
28.
Hornykiewicz O. Parkinson's Disease and its chemotherapy. Biochem Pharmacol. 1975;24:1061–5. [PubMed: 239718]
29.
Hely M A, Fung V S C, Morris J G L. Treatment of Parkinson's Disease. J Clin Neurosci. 2000;7:484–94. [PubMed: 11029227]
30.
Stroudley J, Walsh M. Radiological assessment of dysphagia in Parkinson's Disease. Br J Radiol. 1991;64:890–3. [PubMed: 1954529]
31.
Ramig L O, Countryman S, O'Brien C. et al. Intensive speech treatment for patients with Parkinson's Disease: Short- and long-term comparison of two techniques. Neurology. 1996;47:1496–504. [PubMed: 8960734]
32.
Ramig L O, Sapir S, Fox C. et al. Changes in vocal loudness following intensive voice treatment in individuals with Parkinson's Disease: A comparison with untreated patients and normal age-matched controls. Mov Disord. 2001;16:79–83. [PubMed: 11215597]
33.
Schulz G M, Grant M K. Effects of speech therapy and pharmacologic and surgical treatments on voice and speech in Parkinson's Disease: A review of the literature. J Commun Disord. 2000;33:59–88. [PubMed: 10665513]
34.
Razmy A, Shapiro C M. Interactions of sleep and Parkinson's Disease. Semin Clin Neuropsychiatry. 2000;5:20–32. [PubMed: 10704535]
35.
Marsh L. Neuropsychiatric aspects of Parkinson's Disease. Psychosomatics. 2000;41:15–23. [PubMed: 10665264]
36.
Mindham R H S. The place of dementia in Parkinson's Disease: A methodologic saga. Parkinson's Disease: Advances in Neurology. 1999;80:403–8. [PubMed: 10410748]
37.
Reid W G J, Hely M A, Morris J G L. et al. A longitudinal study of Parkinson's Disease: Clinical and neuropsychological correlates of dementia. J Clin Neurosci. 1996;3:327–33. [PubMed: 18638897]
38.
Katzen H L, Levin B E, Llabre M L. Age of disease onset influences cognition in Parkinson's Disease. J Int Neuropsychol Soc. 1998;4:285–90. [PubMed: 9623003]
39.
Gotham A M, Brown R G, Marsden C D. Depression in Parkinson's Disease: A quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry. 1986;49:381–9. [PMC free article: PMC1028762] [PubMed: 3701347]
40.
Ward C D, Gibb W R. Research diagnostic criteria for Parkinson's Disease. Adv Neurol. 1990;53:245–9. [PubMed: 2239463]
41.
Gibb W R G, Lees A J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's Disease. J Neurol Neurosurg Psychiatry. 1988;51:745–52. [PMC free article: PMC1033142] [PubMed: 2841426]
42.
Hughes A J, Daniel S E, Kilford L. et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:1142–6. [PMC free article: PMC1014720] [PubMed: 1564476]
43.
Hughes A J, Ben-Shlomo Y, Daniel S E. What features improve the accuracy of clinical diagnosis in Parkinson's Disease: A clinicopathologic study. Neurology. 1992;42:1142–6. [PubMed: 1603339]
44.
Rajput A H, Rodzilsky B, Rajput A. Accuracy of clinical diagnosis of Parkinsonism - a prospective study. Can J Neurol Sci. 1991;18:275–8. [PubMed: 1913360]
45.
Clarke C E, Davies P. Systematic review of acute L-dopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's Disease. J Neurol Neurosurg Psychiatry. 2000;69:590–4. [PMC free article: PMC1763425] [PubMed: 11032609]
46.
Brooks D J. PET and SPECT studies in Parkinson's Disease. Baillieres Clin Neurol. 1997;6:69–87. [PubMed: 9426869]
47.
Antonini A, Leenders K L, Meier D. et al. T2 relaxation time in patients with Parkinson's Disease. Neurology. 1993;43:697–700. [PubMed: 8469325]
48.
Wszolek Z K, Markopoulou K. Olfactory dysfunction in Parkinson's Disease. Clin Neurosci. 1998;5:94–101. [PMC free article: PMC497039] [PubMed: 10785834]
49.
Liberini P, Parola S, Spano P F. et al. Olfaction in Parkinson's Disease: Methods of assessment and clinical relevance. J Neurol. 2000;247:88–96. [PubMed: 10751109]
50.
Mesholam R I, Moberg P J, Mahr R N. et al. Olfaction in neurodegenerative disease: a meta-analysis of olfactory functioning in Alzheimer's and Parkinson's Diseases. Arch Neurol. 1998;55:84–90. [PubMed: 9443714]
51.
Horstink MW and Morrish PK. Preclinial diagnosis of Parkinson's Disease. Parkinson's Disease: Advances in Neurology. vol 80, 1999, Philadelphia: Lippincott Williams & Wilkins, pp. 327–33. [PubMed: 10410737]
52.
Stacy M, Jankovic J. Differential diagnosis of Parkinson's Disease and the Parkinsonism plus syndromes. Neurol Clin. 1992;10:341–59. [PubMed: 1584178]
53.
Fahn S, Marsden CD, Calne DB, et al., eds. Recent Developments in Parkinson's Disease. vol 2. Florham Park, NJ. MacMillan Health Care Information 1987; pp 153–63, 293–304.
54.
Martinez-Martin P, Fontan C, Payo B F. et al. Parkinson's Disease: Quantification of disability based on the Unified Parkinson's Disease Rating Scale. Neurologia. 2000;15:382–7. [PubMed: 11195144]
55.
Martinez-Martin P, Gil-Nagel A, Gracia L M. et al. Unified Parkinson's Disease Rating Scale characteristics and structure. Mov Disord. 1994;9:76–83. [PubMed: 8139608]
56.
Hoehn M M, Yahr M D. Parkinsonism: Onset, progression, and mortality. Neurology. 1967;17:427–442. [PubMed: 6067254]
57.
Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson's Disease. In Gillingham FJ, Donaldson IML, eds. Third Symposium of Parkinson's Disease. Edinburgh, Scotland: E&S Livingstone; 1969. p 152–7.
58.
Lang A E, Lozano A M. Parkinon's Disease: Second of two parts. N Engl J Med. 1998;339:1130–43. [PubMed: 9770561]
59.
Hauser R A, Zesiewicz T A. Management of early Parkinson's Disease. Med Clin North Am. 1999;83:393–414. [PubMed: 10093585]
60.
Simon D K, Standaert D G. Parkinson's Disease and parkinsonian syndromes: Neuroprotective therapies. Med Clin North Am. 1999;83:509–23. [PubMed: 10093591]
61.
Stacy M. Managing late complications of Parkinson's Disease. Med Clin North Am. 1999;83:469–81. [PubMed: 10093588]
62.
Fehling C. Treatment of Parkinson's syndrome with L-dopa. A double blind study. Acta Neurol Scand. 1966;42:367–72. [PubMed: 5327616]
63.
Pincus J H, Barry K. Influence of dietary protein on motor fluctuations in Parkinson's Disease. Arch Neurol. 1987;44:270–2. [PubMed: 3827678]
64.
Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's Disease. Brain. 2000;123:2297–305. [PubMed: 11050029]
65.
Rascol O, Brooks D J, Korczyn A D. et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's Disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342:1484–91. [PubMed: 10816186]
66.
Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson's Disease: A randomized controlled trial. JAMA. 2000;284:1931–8. [PubMed: 11035889]
67.
Agid Y, Ahlskog E, Albanese A. et al. Levodopa in the treatment of Parkinson's Disease: A consensus meeting. Mov Disord. 1999;14:911–13. [PubMed: 10584663]
68.
Jankovic J. New and emerging therapies for Parkinson Disease. Arch Neurol. 1999;56:785–90. [PubMed: 10404979]
69.
Mendis T, Suchowersky O, Lang A. et al. Management of Parkinson's Disease: A review of current and new therapies. Can J Neurol Sci. 1999;26:89–103. [PubMed: 10352867]
70.
Fahn S. Parkinson Disease, the effect of levodopa, and the ELLDOPA trial. Arch Neurol. 1999;56:529–35. [PubMed: 10328247]
71.
Calne D B, Teychenne P F, Leigh P H N. et al. Treatment of parkinsonism with bromocriptine. Lancet. 1974;2:1355–6. [PubMed: 4143315]
72.
Ramaker C, Johan W T, van de Beek M S. The efficacy and safety of adjunct bromocriptine therapy for levodopa-induced motor complications: A systematic review. Mov Disord. 2000;15:56–64. [PubMed: 10634242]
73.
van Hilten JJ, Ramaker C, van de Beek WJT, et al. Bromocriptine for levodopa-induced motor complications in Parkinson's Disease (Cochrane Review). In: The Cochrane Library, Issue 4, 2000. Oxford: Update Software. [PMC free article: PMC7032627] [PubMed: 10796755]
74.
Montastruc J L, Rascol O, Senard J M. Treatment of Parkinson's Disease should begin with a dopamine agonist. Mov Disord. 1999;14:725–30. [PubMed: 10495032]
75.
Factor S A. Dopamine agonists. Med Clin North Am. 1999;83:415–43. [PubMed: 10093586]
76.
Clarke CE, Speller JM. Pergolide for levodopa-induced complications in Parkinson's Disease (Cochrane Review). In: The Cochrane Library, Issue 4, 2000. Oxford: Update Software. [PubMed: 10796704]
77.
Clarke CE, Speller JM. Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's Disease (Cochrane Review). In: The Cochrane Library, Issue 4, 2000. Oxford: Update Software. [PubMed: 10796705]
78.
Clarke CE, Speller JM. Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's Disease (Cochrane Review). In: The Cochrane Library, Issue 4, 2000. Oxford: Update Software. [PMC free article: PMC7028005] [PubMed: 10796800]
79.
Clarke CE, Speller JM. Lisuride for levodopa-induced complications in Parkinson's Disease (Cochrane Review). In: The Cochrane Library, Issue 4, 2000. Oxford: Update Software. [PMC free article: PMC7025784] [PubMed: 10796801]
80.
Snow B J, Macdonald L, Mcauley D. et al. The effect of amantadine of levodopa-induced dyskinesias in Parkinson's Disease: A double-blind, placebo-controlled study. Clin Neuropharmacol. 2000;23:82–5. [PubMed: 10803797]
81.
Shoulson I. Parkinson Study Group. Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP). Acta Neurol Scand. 1989;126:171–5. [PubMed: 2515723]
82.
Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's Disease. N Engl J Med. 1993;328:176–83. [PubMed: 8417384]
83.
Tatton W G, Wadia J S, Ju W Y. et al. Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. J Neural Transm. 1996;48:45–59. [PubMed: 8988461]
84.
Magyar K, Haverle D. Neuroprotective and neuronal rescue effects of selegiline. Neurobiology. 1999;7:175–90. [PubMed: 10591051]
85.
Jorga K, Fotteler B, Sedek G. et al. The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation. J Neurol. 1998;245:223–30. [PubMed: 9591224]
86.
Rajput A H, Martin W, Saint-Hilaire M H. et al. Tolcapone improves motor function in parkinsonian patients with the “wearing-off” phenomenon: A double-blind, placebo-controlled, multicenter trial. Neurology. 1997;49:1066–71. [PubMed: 9339691]
87.
Assal F, Spahr L, Hadengue A. et al. Tolcapone and fulminant hepatitis. Lancet. 1998;352:1478. [PubMed: 9752821]
88.
Olanow C W. Tolcapone and hepatotoxic effects. Tasmar Advisory Panel. Arch Neurol. 2000;57:263–7. [PubMed: 10681087]
89.
Martin W E, Loewenson R B, Resch J A. et al. A controlled study comparing trihexyphenidyl hydrochloride plus levodopa with placebo plus levodopa in patients with Parkinson's Disease. Neurology. 1974;24:912–9. [PubMed: 4606107]
90.
Miller E, Berrios G E, Politynska B. The adverse effect of benzhexol on memory in Parkinson's Disease. Acta Neurol Scand. 1987;76:278–82. [PubMed: 3687379]
91.
Idanpaan-Heikkila J, Alhava E, Olkinuora M. et al. Agranulocytosis during treatment with clozapine. Eur J Clin Pharmacol. 1977;11:193–8. [PubMed: 856603]
92.
Lieberman J A, Johns C A, Kane J M. et al. Clozapine-induced agranulocytosis: Non-cross-reactivity with other psychotropic drugs. J Clin Psychiatry. 1988;49:271–7. [PubMed: 3391979]
93.
Selby G. Stereotactic surgery for the relief of Parkinson's Disease. J Neurol Sci. 1967;5:343–75. [PubMed: 4862131]
94.
Arle J E, Alterman R L. Surgical options in Parkinson's Disease. Med Clin North Am. 1999;83:483–98. [PubMed: 10093589]
95.
Uitti R J. Surgical treatments for Parkinson's Disease. Can Fam Phys. 2000;46:368–73. [PMC free article: PMC1987687] [PubMed: 10690493]
96.
Bronstein J M, DeSalles A, DeLong M R. Stereotactic pallidotomy in the treatment of Parkinson's Disease: An expert opinion. Arch Neurol. 1999;56:1064–9. [PubMed: 10488806]
97.
Hallett M, Litvan I. Evaluation of surgery for Parkinson's Disease: A report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 1999;53:1910–21. [PubMed: 10599758]
98.
Lozano A M, Lang A E, Galvez-Jiminez N. et al. Effect of GPi pallidotomy on motor function in Parkinson's Disease. Lancet. 1995;346:1383–7. [PubMed: 7475819]
99.
Fields J A, Troster A I. Cognitive outcomes after deep brain stimulation for Parkinson's Disease: A review of initial studies and recommendations for future research. Brain Cogn. 2000;42:268–93. [PubMed: 10744924]
100.
Schuurman P R, Bosch D A, Bossuyt P M M. et al. A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. N Eng J Med. 2000;342:461–8. [PubMed: 10675426]
101.
Koller W C, Pahwa R, Lyons K E. et al. Surgical treatment of Parkinson's Disease. J Neurol Sci. 1999;167:1–10. [PubMed: 10500254]
102.
Backlund E O, Granberg P O, Hamberger B. et al. Transplantation of adrenal medullary tissue to striatum in parkinsonism: First clinical trials. J Neurosurg. 1985;62:169–73. [PubMed: 2578558]
103.
Freed C R, Greene P E, Breeze R E. et al. Transplantation of embryonic dopamine neurons for severe Parkinson's Disease. N Engl J Med. 2001;344:710–9. [PubMed: 11236774]
104.
Langston J W, Widner H, Goetz C G. et al. Core Assessment Program for Intracerebral Transplantations. Mov Disord. 1992;7:2–13. [PubMed: 1557062]
105.
Defer G L, Widner H, Marie R M. et al. Core Assessment Program for Surgical Interventional Therapies in Parkinson's Disease (CAPSIT-PD). Mov Disord. 1999;14:572–84. [PubMed: 10435493]
106.
Clarke C E, Zobkiw R M. Quality of life and care in Parkinson's Disease. Brit J Clin Pract. 1995;49:288–93. [PubMed: 8554950]
107.
Hildick-Smith M. Pragmatic physical therapy in Parkinson's Disease: Any scientific basis? Parkinson's Disease: Advances in Neurology. 1999;80:561–4. [PubMed: 10410772]
108.
Johnson J A, Pring T R. Speech therapy and Parkinson's Disease: A review and further data. Br J Disord Commun. 1990;25:183–94. [PubMed: 2206966]
109.
Johnson B T, Qun L, Castell J A. et al. Swallowing and esophageal function in Parkinson's Disease. Amer J Gastroenterol. 1995;90:1741–6. [PubMed: 7572887]
110.
Mulrow C, Cook D J, Davidoff F. Systematic reviews: critical links in the great chain of evidence. Ann Intern Med. 1997;126:389–91. [PubMed: 9054284]
111.
Sacks H S, Berrier J, Reitman D. et al. Meta-analyses of randomized controlled trials. N Engl J Med. 1987;316:450–5. [PubMed: 3807986]
112.
Jadad A R, Moore A, Carroll D. et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Controlled Clinical Trials. 1996;17:1–12. [PubMed: 8721797]
113.
Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. CMAJ 1998: 158. [PubMed: 9484271]
114.
Hely M A, Chey T, Wilson A. et al. Reliability of the Columbia scale for assessing signs of Parkinson's Disease. Mov Disord. 1993;8:466–72. [PubMed: 8232356]
115.
Canter G J, deLaTorre R, Mier M. A method for evaluating disability in patients with Parkinson's Disease. J Nerv Ment Dis. 1961;133:143–7. [PubMed: 13876261]
116.
Hedges L, Olkin I. Statistical Methods for Meta-Analysis. 1985. New York: Academic Press.
117.
Raudenbush SW. The Handbook of Research Synthesis. New York: Russell Sage Foundation; 1994. Chapter 20, Random Effects Models.
118.
Hedges LV. The Handbook of Research Synthesis. New York: Russell Sage Foundation; 1994. Chapter 19, Fixed Effects Models.
119.
Bromocriptine Multicentre Trial Group. Bromocriptine as initial therapy in elderly parkinsonian patients. Age Aging. 1990;19:62–7. [PubMed: 2180259]
120.
Irwig L, Tosteson A N A, Gatsonis C. et al. Guidelines for meta-analyses evaluating diagnostic tests. Ann Intern Med. 1994;120:667–76. [PubMed: 8135452]
121.
D'Costa D F, Abbot R J, Pye I F. et al. The apomorphine test in parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 1991;10:870–2. [PMC free article: PMC1014569] [PubMed: 1744640]
122.
Hughes A J, Lees A J, Stern G M. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet. 1990;336:32–4. [PubMed: 1973218]
123.
Hughes A J, Lees A J, Stern G M. Challenge tests to predict the dopaminergic response in untreated Parkinson's Disease. Neurology. 1991;41:1723–5. [PubMed: 1944899]
124.
Gasser T, Schwarz J, Arnold G. et al. Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson's Disease. Arch Neurol. 1992;49:1131–4. [PubMed: 1444878]
125.
Bonucelli U, Picini P, Del Dotto P. et al. Apomorphine test for dopaminergic responsiveness: A dose assessment study. Mov Disord. 1993;8:158–64. [PubMed: 8474482]
126.
Schwarz J, Linke R, Kerner M. et al. Striatal dopamine transporter binding assessed by [I-123_IPT and single photon emission computed tomography in patients with early Parkinson' Disease: Implications for a preclinical diagnosis. Arch Neurol. 2000;57:205–8. [PubMed: 10681078]
127.
Schwarz J, Kraft E, Vogl T. et al. Relative quantification of signal on T2-weighted images in the basal ganglia: Limited value in differential diagnosis of patients with parkinsonism. Neuroradiology. 1999;41:124–7. [PubMed: 10090605]
128.
Schwarz J, Tatsch K, Gasser T. et al. 123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism. Mov Disord. 1998;13:16–9. [PubMed: 9452320]
129.
Schwarz J, Antonini A, Tatsch K. et al. Comparison of 123I-IBZM SPECT and 11C-raclopride PET findings in patients with parkinsonism. Nucl Med Commun. 1994;15:806–13. [PubMed: 7838444]
130.
Schwarz J, Tatsch K, Arnold G. et al. 123I-iodobenzamide-SPECT in 83 patients with de novo parkinsonism. Neurology. 1993;43:S17–20. [PubMed: 8264906]
131.
Schwarz J, Tatsch K, Gasser T. et al. [123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy. Mov Disord. 1997;12:898–902. [PubMed: 9399212]
132.
Schelosky L, Hierholzer J, Wissel J. et al. Correlation of clinical response in apomorphine test with D2 receptor status as demonstrated by 123I IBZM-SPECT. Mov Disord. 1993;8:453–8. [PubMed: 8232354]
133.
Booij J, Tissingh G, Boer G J. et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's Disease. J Neurol Neurosurg Psychiatry. 1997;62:133–40. [PMC free article: PMC486723] [PubMed: 9048712]
134.
Tatsch K, Schwarz J, Oertel W H. et al. SPECT imaging of dopamine D2 receptors with 123I-IBZM: Initial experience in controls and patients with Parkinson's syndrome and Wilson's disease. Nucl Med Commun. 1991;12:699–707. [PubMed: 1838142]
135.
Giobbe D, Castellano G C, Podio V. Dopamine D2 receptor imaging with SPECT using IBZM in 16 patients with Parkinson's Disease. Ital J Neurol Sci. 1993;14:165–9. [PubMed: 8509271]
136.
Pizzolato G, Cagnin A, Rossato A. et al. Striatal dopamine D2 receptor alterations and response to L-dopa in Parkinson's Disease. Adv Neurol. 1996;69:467–73. [PubMed: 8615167]
137.
Imon Y, Matsuda H, Ogawa M. et al. SPECT image analysis using statistical parametric mapping in patients with Parkinson's Disease. J Nucl Med. 1999;40:1583–9. [PubMed: 10520695]
138.
Seibyl J P, Marek K L, Quinlan D. et al. Decreased single-photon emission computed tomographic [123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's Disease. Ann Neurol. 1995;38:589–98. [PubMed: 7574455]
139.
Kaasinen V, Nagren K, Hietala J. et al. Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's Disease. Neurology. 2000;54:1482–7. [PubMed: 10751262]
140.
Rinne J O, Portin R, Ruottinen H. et al. Cognitive impairment and the brain dopaminergic system in Parkinson's Disease: [18F]fluorodopa positron emission tomographic study. Arch Neurol. 2000;57:470–5. [PubMed: 10768619]
141.
Rinne J O, Laihinen A, Ruottinen H. et al. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in earl Parkinson's Disease: A PET study with [11C] raclopride. J Neurol Sci. 1995;132:156–61. [PubMed: 8543941]
142.
Burn D J, Sawle G V, Brooks D J. Differential diagnosis of Parkinson's Disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. J Neurol Neurosurg Psychiatry. 1994;57:278–84. [PMC free article: PMC1072814] [PubMed: 8158173]
143.
Morrish P K, Sawle G V, Brooks D J. Clinical and [18F] dopa PET findings in early Parkinson's Disease. J Neurol Neurosurg Psychiatry. 1995;59:597–600. [PMC free article: PMC1073753] [PubMed: 7500096]
144.
Sawle G V, Playford E D, Burn D J. et al. Separating Parkinson's Disease from normality. Discriminant functin analysis of flurodopa F 18 positron emission tomography data. Arch Neurol. 1994;51:237–43. [PubMed: 8129633]
145.
Eidelberg D, Moeller J R, Ishikawa T. et al. Early differential diagnosis of Parkinson's Disease with18F-fluorodeoxyglucose and positron emission tomography. Neurology. 1995;45:1995–2004. [PubMed: 7501148]
146.
Otsuka M, Ichiya Y, Hosokawa S. et al. Striatal blood flow, glucose metabolism and 18F-Dopa uptake: Difference in Parkinson's Disease and atypical parkinsonism. J Neurol Neurosurg Psychiatry. 1991;54:898–904. [PMC free article: PMC1014575] [PubMed: 1744644]
147.
Kraft E, Schwarz J, Trenkwalder C. et al. The combination of hypointense and hyperintense signal changes on T2-weighted magnetic resonance imaging sequences: A specific marker of multiple system atrophy? Arch Neurol. 1999;56:225–8. [PubMed: 10025428]
148.
Ryvlin P, Broussole E, Piollet H. et al. Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson's Disease. Arch Neurol. 1995;52:583–8. [PubMed: 7763206]
149.
Holshouser B A, Komu M, Moller H E. et al. Localized proton NMR spectroscopy in the striatum of patients with idiopathic Parkinson's Disease: A multicenter pilot study. Magn Reson Med. 1995;33:589–94. [PubMed: 7596261]
150.
Becker G, Seufert J, Bogdahn U. et al. Degeneration of substantia nigra in chronic Parkinson's Disease visualized by transcranial color-coded real-time sonography. Neurology. 1995;45:182–4. [PubMed: 7824114]
151.
Meara J, Bhowmick B K, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's Disease. Age Ageing. 1999;28:99–102. [PubMed: 10350403]
152.
Jankovic J, Rajput A H, McDermott M P. et al. The evolution of diagnosis in early Parkinson Disease. Arch Neurol. 2000;57:369–72. [PubMed: 10714663]
153.
Buttner T, Kuhn W, Muller T. et al. Distorted color discrimination in de novo parkinsonian patients. Neurology. 1995;45:386–7. [PubMed: 7854545]
154.
Buttner T, Kuhn W, Patzold T. et al. L-dopa improves color vision in Parkinson's Disease. J Neural Transm. 1994;7:13–9. [PubMed: 8579766]
155.
Delalande I, Destee A, Hache J C. et al. Visual evoked potentials and spatiotemporal contrast sensitivity changes in idiopathic Parkinson's Disease and multiple system atrophy. Adv Neurol. 1996;69:319–25. [PubMed: 8615146]
156.
Relja M A, Petravic D, Kolaj M. Quantifying rigidity with a new computerized elbow device. Clin Neuropharmacol. 1996;19:148–56. [PubMed: 8777768]
157.
Fung V S C, Burne J A, Morris J G L. Objective quantification of resting and activated parkinsonian rigidity: A comparison of angular impulse and work scores. Mov Disord. 2000;15:48–55. [PubMed: 10634241]
158.
Caronti B, Tanda G, Colosimo C. et al. Reduced dopamine in peripheral blood lymphocytes in Parkinson's Disease. NeuroReport. 1999;10:2907–10. [PubMed: 10549795]
159.
Arnold G, Bondy B, Bandmann O. et al. 3H-spiperone binding to lymphocytes fails in the differential diagnosis of de novo Parkinson syncromes. J Neral Transm. 1993;5:107–16. [PubMed: 7687443]
160.
Bellomo G, Santambrogio L, Fiacconi M. et al. Plasma profiles of adrenocorticotropic hormone, cortisol, growth hormone and prolactin in patients with untreated Parkinson's Disease. J Neurol. 1991;238:19–22. [PubMed: 1851513]
161.
Espino A, Calopa M, Ambrosio S. et al. CSF somatostatin increase in patients with early parkinsonian syndrome. J Neural Transm. 1995;9:189–96. [PubMed: 8527003]
162.
Jiminez-Jiminez F J, Rubio J C, Molina J A. et al. Cerebrospinal fluid carnitine levels in patients with Parkinson's Disease. J Neurol Sci. 1997;145:183–5. [PubMed: 9094047]
163.
Murofushi T, Mizuno M, Osanai R. et al. Olfactory dysfunction in Parkinson's Disease. J Otorhinol Relat Spec. 1991;53:143–6. [PubMed: 1852411]
164.
Sakuma K, Nakashima K, Takahashi K. Olfactory evoked potentials in Parkinson's Disease, Alzheimer's disease, and anosmic patients. Psychiatry Clin Neurosci. 1996;50:35–40. [PubMed: 9201769]
165.
Doty R L, Stern M B, Pfeiffer C. et al. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's Disease. J Neurol Neurosurg Psychiatry. 1992;55:138–42. [PMC free article: PMC488979] [PubMed: 1538221]
166.
Doty R L, Golbe L I, McKeown B A. et al. Olfactory testing differentiates between progressive supranuclear palsy and idiopathic Parkinson's Disease. Neurology. 1993;43:962–5. [PubMed: 8492953]
167.
Hawkes C H, Shephard B C. Olfactory evoked responses and identification tests in neurological disease. Ann NY Acad Sci. 1998;855:608–15. [PubMed: 9929657]
168.
Potagas C, Dellatolas G, Ziegler M. et al. Clinical assessment of olfactory dysfunction in Parkinson's Disease. Mov Disord. 1998;13:394–9. [PubMed: 9613727]
169.
Lehrner J P, Brucke T, Dal-Bianco P. et al. Olfactory functions in Parkinson's Disease and Alzheimer's Disease. Chem Senses. 1997;22:105–10. [PubMed: 9056090]
170.
Montgomery E B, Koller W C, LaMantia T J K. et al. Early detection of probable idiopathic Parkinson's Disease: I. Development of a diagnostic test battery. Mov Disord. 2000;15:467–73. [PubMed: 10830410]
171.
Montgomery E B, Lyons K, Koller W D. Early detection of probable idiopathic Parkinson's Disease: II. A prospective application of a diagnostic test battery. Mov Disord. 2000;15:474–8. [PubMed: 10830411]
172.
Montgomery E B, Baker K B, Lyons K. et al. Abnormal performance on the PD test battery by asymptomatic first-degree relatives. Neurology. 1999;52:757–62. [PubMed: 10078723]
173.
Rajput A H, Rozdilsky B, Ang L. Occurrence of resting tremor in Parkinson's Disease. Neurology. 1991;41:1298–9. [PubMed: 1866022]
174.
Litvan I, MacIntyre A, Goetz C G. et al. Accuracy of the clinical diagnoses of Lewy Body Disease, Parkinson Disease, and dementia with Lewy bodies: A clinicopathologic study. Arch Neurol. 1998;55:969–78. [PubMed: 9678315]
175.
Louis E K, Klatka L A, Liu Y. et al. Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson's Disease. Neurology. 1997;48:376–80. [PubMed: 9040725]
176.
Wenning G K, Ebersbach G, Verny M. et al. Progression of falls in postmortem-confirmed parkinsonian disorders. Mov Disord. 1999;14:947–50. [PubMed: 10584668]
177.
Parkinson Study Group. Entcapone improves motor fluctuations in levodopa-treated Parkinson's Disease patients. Ann Neurol. 1997;42:747–55. [PubMed: 9392574]
178.
Allain H, Destee A, Petit H. et al. Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's Disease. Eur Neurol. 2000;44:22–30. [PubMed: 10894991]
179.
Baas H, Beiske A G, Ghika J. et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the “wearing off” phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry. 1997;63:421–8. [PMC free article: PMC2169755] [PubMed: 9343116]
180.
Kulisevsky J, Garcia-Sanches C, Berthier M L. et al. Chronic effects of dopaminergic replacement on cognitive function in Parkinson's Disease. A two-year follow-up study of previously untreated patients. Mov Disord. 2000;15:613–26. [PubMed: 10928571]
181.
Larsen J P, Boas J, Erdal J E. et al. Does selegiline modify the progression of early Parkinson's Disease? Results from a five-year study. Eur J Neurol. 1999;6:539–47. [PubMed: 10457386]
182.
Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's Disease: Results of a double-blind, placebo-controlled, parallel-group study. Neurology. 1997;49:162–8. [PubMed: 9222185]
183.
Olanow C W, Fahn S, Muenter M. et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's Disease. Mov Disord. 1994;9:40–7. [PubMed: 8139604]
184.
Kunig G, Pogarell O, Moller J C. et al. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's Disease. Clin Neuropharmacol. 1999;22:301–5. [PubMed: 10516884]
185.
Steiger M J, El-Debas T, Anderson T. et al. Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. J Neurol. 1996;243:68–72. [PubMed: 8869390]
186.
Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's Disease. Neurology. 1997;49:1060–5. [PubMed: 9339690]
187.
Martignoni E, Pachetti C, Sibilla L. et al. Dihydroergocryptine in the treatment of Parkinson's Disease: A six months' double-blind clinical trial. Clin Neuropharmacol. 1991;14:78–83. [PubMed: 1903079]
188.
Olsson J E. Bromocriptine and levodopa in early combination in Parkinson's Disease: First results of the collaborative European multicentric trial. Adv Neurol. 1990;53:421–3. [PubMed: 2239483]
189.
Waters C H, Kurth M, Bailey P. et al. Tolcapone in stable Parkinson's Disease: Efficacy and safety of long-term treatment. Neurology. 1997;49:665–71. [PubMed: 9305320]
190.
Hutton J T, Koller W C, Ahlskog J E. et al. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's Disease. Neurology. 1996;46:1062–5. [PubMed: 8780092]
191.
Inzelberg R, Nisipeanu P, Rabey J M. et al. Double-blind comparison of cabergoline aned bromocriptine in Parkinson's Disease patients with motor fluctuations. Neurology. 1996;47:785–8. [PubMed: 8797480]
192.
MacMahon D G, Overstall P W, Marshall T. Simplification of the initiation of bromocriptine in elderly patients with advanced Parkinson's Disease. Age Ageing. 1991;20:146–51. [PubMed: 2053506]
193.
Rabey J M, Streifler M, Treves T. et al. The beneficial effect of chronic lisuride administration compared with levodopa in Parkinson's Disease. Adv Neurol. 1990;53:451–5. [PubMed: 2122652]
194.
Wolters E C, Tesselaar H J. International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson's Disease. J Neurol. 1996;243:235–40. [PubMed: 8936353]
195.
Alarcon F. Does combined levodopa and bromocriptine therapy in Parkinson's Disease prevent late motor complications? Eur J Neurol. 1998;5:255–63. [PubMed: 10210840]
196.
Bergamasco B, Frattola L, Muratorio A. et al. Alpha-dihydroergocryptine in the treatment of de novo parkinsonian patients: Results of a multicentre, randomized, double-blind, placebo-controlled study. Acta Neurol. 2000;101:372–80. [PubMed: 10877152]
197.
Dupont E, Andersen A, Boas J. et al. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand. 1996;93:14–20. [PubMed: 8825266]
198.
Koller W C, Hutton J T, Tolosa E. et al. Immediate-release and controlled-release carbidopa/levodopa in PD: A 5-year randomized multicenter study. Neurology. 1999;53:1012–9. [PubMed: 10496260]
199.
Montastruc J L, Rascol O, Senard J M. et al. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's Disease: A five year follow up. J Neurol Neurosurg Psychiatry. 1994;57:1034–8. [PMC free article: PMC1073123] [PubMed: 8089666]
200.
Myllyla V V, Sotaniemi K A, Vuorinen J A. et al. Selegiline as initial treatment in de novo parkinsonian patients. Neurology. 1992;42:339–43. [PubMed: 1736162]
201.
Nappi G, Martignoni E, Horowski R. et al. Lisuride plus selegiline in the treatment of early Parkinson's Disease. Acta Neurol Scand. 1991;83:407–10. [PubMed: 1909485]
202.
Palhagen S, Heinonen E H, Hagglund J. et al. Selegiline delays the onset of disability in de novo parkinsonian patients. Neurology. 1998;51:520–5. [PubMed: 9710028]
203.
Rinne U K, Bracco F, Chouza C. et al. Early treatment of Parkinson's Disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. Drugs. 1998;55:23–30. [PubMed: 9483167]
204.
Weiner W J, Factor S A, Sanchez-Ramos J R. et al. Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's Disease. Neurology. 1993;43:21–7. [PubMed: 8423888]
205.
Hely M A, Morris J G, Reid W G. et al. The Sydney multicentre study of Parkinson's Disease: A randomised, prospective five-year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry. 1994;57:903–10. [PMC free article: PMC1073071] [PubMed: 8057111]
206.
Korczyn A D, Brunt E R, Larsen J P. et al. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's Disease. Neurology. 1999;53:364–70. [PubMed: 10430427]
207.
Lees A J. Parkinson's Disease Research Group in the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's Disease. BMJ. 1995;311:1602–7. [PMC free article: PMC2551499] [PubMed: 8555803]
208.
Olanow C W, Hauser R A, Gauger L. et al. The effect of deprenyl and levodopa on the progression of Parkinson's Disease. Ann Neurol. 1995;38:771–7. [PubMed: 7486869]
209.
Przuntek H, Welzel D, Gerlach M. et al. Early institution of bromocriptine in Parkinson's Disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study. J Neural Transm Park Dis Dement Sect. 1996;103:699–715. [PubMed: 8836932]
210.
Przuntek H, Conrad B, Dichgans J. et al. SELEDO: A 5-year long-term trial on the effect of selegiline in early parkinsonian patients treated with levodopa. Eur J Neurol. 1999;6:141–50. [PubMed: 10053226]
211.
Parkinson Study Group. Effect of lazabemide on the progression of disability in early Parkinson's Disease. Ann Neurol. 1996;40:99–107. [PubMed: 8687199]
212.
Sethi K D, O'Brien C F, Hammerstad J P. et al. Ropinirole for the treatment of early Parkinson Disease: A 12-month experience. Arch Neurol. 1998;55:1211–6. [PubMed: 9740115]
213.
Shannon K M, Bennett J P J, Friedman J H. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's Disease. Neurology. 1997;49:724–8. [PubMed: 9305331]
214.
Bakheit A M, Henderson L M, Moore A P. et al. Long-term double masked trial of early treatment with L-dopa plus bromocriptine versus L-dopa alone in Parkinson's Disease. Interim results. Eur Neurol. 1990;30:108–11. [PubMed: 2340834]
215.
Giminez-Roldan S, Tolosa E, Burguera J A. et al. Early combination of bromocriptine and levodopa in Parkinson's Disease: A prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage. Clin Neuropharmacol. 1997;20:67–76. [PubMed: 9037575]
216.
Nakanishi T, Iwata M, Goto I. et al. Nation-wide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients. Final report. Eur Neurol. 1992;32:9–22. [PubMed: 1425821]
217.
Kleedorfer B, Poewe W. Comparative efficacy of two oral sustained-release preparations of L-dopa in fluctuating Parkinson's Disease. Preliminary findings in 20 patients. J Neural Transm [P-D Sect] 1992;4:173–8. [PubMed: 1571080]
218.
Stocchi F, Bramante L, Monge A. et al. Apomorphine and lisuride infusion. A comparative chronic study. Adv Neurol. 1993;60:653–5. [PubMed: 8420205]
219.
Lieberman A, Olanow C W, Sethi K. et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's Disease. Neurology. 1998;51:1057–62. [PubMed: 9781529]
220.
Rinne U K, Larsen J P, Siden A. et al. Entcapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology. 1998;51:1309–14. [PubMed: 9818851]
221.
de Bie R M A, de Haan R J, Nijssen P C G. et al. Unilateral pallidotomy in Parkinson's Disease: A randomised, single-blind, multicentre trial. Lancet. 1999;354:1665–9. [PubMed: 10568567]
222.
Young R F, Shumway-Cook A, Vermeulen S S. et al. Gamma knife radiosurgery as a lesioning technique in movement disorder surgery. J Neurosurg. 1998;89:183–93. [PubMed: 9688111]
223.
Baron M S, Vitek J L, Bakay R A E. et al. Treatment of advanced Parkinson's Disease by unilateral posterior GPi pallidotomy: 4-year results of a pilot study. Mov Disord. 2000;15:230–7. [PubMed: 10752571]
224.
Dalvi A, Winfield L, Yu Q. et al. Stereotactic posteroventral pallidotomy: Clinical methods and results at 1-year follow up. Mov Disord. 1999;14:256–61. [PubMed: 10091619]
225.
Desaloms J M, Krauss J K, Lai E C. et al. Posteroventral medial pallidotomy for treatment of Parkinson's Disease: Preoperative magnetic resonance imaging features and clinical outcome. J Neurosurg. 1998;89:194–9. [PubMed: 9688112]
226.
Dewey R B, Giller C A, Broline S K. et al. Clinical outcome of unilateral stereotactic pallidotomy without microelectrode recording for intractable Parkinson's Disease. Parkinsonism Relat. 2000;6:7–16. [PubMed: 18591146]
227.
Dogali M, Sterio D, Fazzini E. et al. Effects of posteroventral pallidotomy on Parkinson's Disease. Adv Neurol. 1996;69:585–90. [PubMed: 8615183]
228.
Eskandar E N, Shinobu L A, Penney J B. et al. Stereotactic pallidotomy performed without using microelectrode guidance in patients with Parkinson's Disease: Surgical technique and 2-year results. J Neurosurg. 2000;92:375–83. [PubMed: 10701522]
229.
Herrera E J, Viano J C, Caceres M. et al. Posteroventral pallidotomy in Parkinson's Disease. Acta Neurochir (Wien). 2000;142:169–75. [PMC free article: PMC300905] [PubMed: 10795891]
230.
Iacono R P, Shima F, Lonser R R. et al. The results, indications, and physiology of posteroventral pallidotomy for patients with Parkinson's Disease. Neurosurgery. 1995;36:1118–27. [PubMed: 7643990]
231.
Johansson F, Malm J, Nordh E. et al. Usefulness of pallidotomy in advanced Parkinson's Disease. J Neurol Neurosurg Psychiatry. 1997;62:125–32. [PMC free article: PMC486722] [PubMed: 9048711]
232.
Kondziolka D, Bonaroti E, Baser S. et al. Outcomes after stereotactically guided pallidotomy for advanced Parkinson's Disease. J Neurosurg. 1999;90:197–202. [PubMed: 9950488]
233.
Lang A E, Lozano A M, Montgomery E. et al. Posteroventral medial pallidotomy in advanced Parkinson's Disease. N Engl J Med. 1997;337:1036–42. [PubMed: 9321531]
234.
Masterman D, DeSalles A, Baloh R W. et al. Motor, cognitive, and behavioral performance following unilateral ventroposterior pallidotomy for Parkinson Disease. Arch Neurol. 1998;55:1201–8. [PubMed: 9740114]
235.
Melnick M E, Dowling G A, Aminoff M J. et al. Effect of pallidotomy on postural control and motor function in Parkinson Disease. Arch Neurol. 1999;56:1361–5. [PubMed: 10555656]
236.
Roberts-Warrior D, Overby A, Jankovic J. et al. Postural control in Parkinsn's Disease after unilateral posteroventral pallidotomy. Brain. 2000;123:2141–9. [PubMed: 11004130]
237.
Samii A, Turnbull I M, Kishore A. et al. Reassessment of unilateral pallidotomy in Parkinson's Disease. A 2-year follow-up study. Brain. 1999;122:417–25. [PubMed: 10094251]
238.
Samuel M, Caputo E, Brooks D J. et al. A study of medial pallidotomy for Parkinson's Disease: Clinical outcome, MRI location and complications. Brain. 1998;121:59–75. [PubMed: 9549488]
239.
Shannon K M, Penn R D, Kroin J S. et al. Stereotactic pallidotomy for the treatment of Parkinson's Disease. Efficacy and adverse effects at 6 months in 26 patients. Neurology. 1998;50:434–8. [PubMed: 9484368]
240.
Taha J M, Favre J, Baumann T K. et al. Tremor control after pallidotomy in patients with Parkinson's Disease: Correlation with microrecording findings. J Neurosurg. 1997;86:642–7. [PubMed: 9120628]
241.
Diederich N, Goetz C G, Stebbins G T. et al. Blinded evaluation confirms long-term asymmetric effect of unilateral thalamotomy or subthalamotomy on tremor in Parkinson's Disease. Neurology. 1992;42:1311–4. [PubMed: 1620340]
242.
Fox M W, Ahlskog J E, Kelly P J. Stereotactic ventrolateralis thalamotomy for medically refractory tremor in post-levodopa era Parkinson's Disease patients. J Neurosurg. 1991;75:723–30. [PubMed: 1919694]
243.
Jankovic J, Hamilton W J, Grossman R G. Thalamic surgery for movement disorders. Adv Neurol. 1997;74:221–3. [PubMed: 9348417]
244.
Ardouin C, Pillon B, Peiffer E. et al. Bilateral subthalamic or pallidal stimulation for Parkinson's Disease affects neither memory nor executive functions: A consecutive series of 62 patients. Ann Neurol. 1999;46:217–23. [PubMed: 10443887]
245.
Bejjani B P, Gervais D, Arnulf I. et al. Axial parkinsonian symptoms can be improved: The role of levodopa and bilateral subthalamic stimulation. J Neurol Neurosurg Psychiatry. 2000;68:595–600. [PMC free article: PMC1736917] [PubMed: 10766889]
246.
Burchiel K J, Anderson V C, Favre J. et al. Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson's Disease: Results of a randomized, blinded pilot study. Neurosurgery. 1999;45:1375–82. [PubMed: 10598706]
247.
Houeto J L, Damier P, Bejjani P B. et al. Subthalamic stimulation in Parkinson Disease: A multidisciplinary approach. Arch Neurol. 2000;57:461–5. [PubMed: 10768618]
248.
Krack P, Pollak P, Limousin P. et al. Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's Disease. Brain. 1998;121:451–7. [PubMed: 9549521]
249.
Limousin P, Krack P, Pollak P. et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's Disease. N Engl J Med. 1998;339:1105–11. [PubMed: 9770557]
250.
Molinuevo J L, Valldeoriola F, Tolosa E. et al. Levodopa withdrawal after bilateral subthalamic nucleus stimulation in advanced Parkinson Disease. Arch Neurol. 2000;57:983–8. [PubMed: 10891980]
251.
Koller W, Pahwa R, Busenbark K. et al. High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. Ann Neurol. 1997;42:292–9. [PubMed: 9307249]
252.
Kumar K, Kelly M, Toth C. Deep brain stimulation of the ventral intermediate nucleus of the thalamus for control of tremors in Parkinson's Disease and essential tremor. Stereotact Funct Neurosurg. 1999;72:47–61. [PubMed: 10640920]
253.
Limousin P, Speelman J D, Gielen F. et al. Multicentre European study of thalamic stimulation in parkinsonian and essential tremor. J Neurol Neurosurg Psychiatry. 1999;66:289–96. [PMC free article: PMC1736277] [PubMed: 10084526]
254.
Goetz C G, Stebbins G E, Klawans H L. et al. United Parkinson Foundation Neurotransplantation Registry on adrenal medullary transplants: presurgical, and 1- and 2-year follow-up. Neurology. 1991;41:1719–22. [PubMed: 1944898]
255.
Lopez-Lozano J J, Bravo G, Abascal J. et al. Grafting of perfused adrenal medullary tissue into the caudate nucleus of patients with Parkinson's Disease. J Neurosurg. 1991;75:234–43. [PubMed: 2072160]
256.
Velasco F, Velasco M, Rodriguez Cuevas H. et al. Autologous adrenal medullary transplants in advanced Parkinson's Disease with particular attention to the selective improvement in symptoms. Stereotact Funct Neurosurg. 1991;57:195–212. [PubMed: 1842977]
257.
Henderson B T, Clough C G, Hughes R C. et al. Implantation of human fetal ventral mesencephalon to the right caudate nucleus in advanced Parkinson's Disease. Arch Neurol. 1991;48:822–7. [PubMed: 1898256]
258.
Kopyov O V, Jacques D, Lieberman A. et al. Clinical study of fetal mesencephalic intracerebral transplants for the treatment of Parkinson's Disease. Cell Transplant. 1996;5:327–37. [PubMed: 8689043]
259.
Kopyov O V, Jacques D S, Lieberman A. et al. Outcome following intrastriatal fetal mesencephalic grafts for Parkinson's patients is directly related to the volume of grafted tissue. Exp Neurol. 1997;146:536–45. [PubMed: 9270065]
260.
Lopez-Lozano J J, Bravo G, Brera B. et al. Long-term improvement in patients with severe Parkinson's Disease after implantation of fetal ventral mesencephalic tissue in a cavity of the caudate nucleus: 5-year follow up in 10 patients. J Neurosurg. 1997;86:931–42. [PubMed: 9171171]
261.
Fink J S, Schumacher J M, Ellias S L. et al. Porcine xenografts in Parkinson's Disease and Huntington's Disease patients: Preliminary results. Cell Transplant. 2000;9:273–8. [PubMed: 10811399]
262.
Wermuth L, Sorensen P S, Timm B. et al. Depression in idiopathic Parkinson's Disease treated with citalopram. Nord J Psychiatry. 1998;52:163–9.
263.
Sano M, Stern Y, Marder K. et al. A controlled trial of piracetam in intellectually impaired patients with Parkinson's Disease. Mov Disord. 1990;5:230–4. [PubMed: 2388639]
264.
Factor S A, Brown D, Molho E S. et al. Clozapine: A two-year open trial in Parkinson's Disease patients with psychosis. Neurology. 1994;44:544–6. [PubMed: 8145929]
265.
Kahn N, Freeman A, Juncos J L. et al. Clozapine is beneficial for psychosis in Parkinson's Disease. Neurology. 1991;41:1699–700. [PubMed: 1922830]
266.
Rabey J M, Treves T A, Neufeld M Y. Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's Disease. Neurology. 1995;45:432–4. [PubMed: 7898690]
267.
Ruggieri S, DePandis M F, Bonamartini A. et al. Low dose of clozapine in the treatment of dopaminergic psychosis in Parkinson's Disease. Clin Neuropharmacol. 1997;20:204–9. [PubMed: 9197942]
268.
Trosch R M, Friedman J H, Lannon M C. et al. Clozapine use in Parkinson's Disease: A retrospective analysis of a large multicentered clinical experience. Mov Disord. 1998;13:377–82. [PubMed: 9613725]
269.
Wagner M L, Defilippi J L, Menza M A. et al. Clozapine for the treatment of psychosis in Parkinson's Disease: Chart review of 49 patients. J Neuropsychiatry Clin Neurosci. 1996;8:276–80. [PubMed: 8854298]
270.
Meco G, Alessandri A, Giustini P. et al. Risperidone in levodopa-induced psychosis in advanced Parkinson's Disease: An open-label, long-term study. Mov Disord. 1997;12:610–2. [PubMed: 9251085]
271.
Targum S D, Abbott J L. Efficacy of quetiapine in parkinson's patients with psychosis. J Clin Psychopharmacol. 2000;20:54–60. [PubMed: 10653209]
272.
Dam M, Tonin P, Casson S. et al. Effects of conventional and sensory-enhanced physiotherapy on disability of Parkinson's Disease patients. Adv Neurol. 1996;69:551–5. [PubMed: 8615180]
273.
Jahanshahi M, Brown R G, Whitehouse C. et al. Contact with a nurse practitioner: A short-term evaluation study in Parkinson's Disease and dystonia. Behav Neurol. 1994;7:189–96. [PubMed: 24487336]
274.
Mally J, Stone T W. Improvement in parkinsonian symptoms after repetitive transcranial magnetic stimulation. J Neurol Sci. 1999;162:179–84. [PubMed: 10202984]
275.
Mercer B S. A randomized study of the efficacy of the PROPATH program for patients with Parkinson's Disease. Arch Neurol. 1996;53:881–4. [PubMed: 8815853]
276.
Montgomery E B, Lieberman A, Singh G. et al. Patient education and health promotion can be effective in Parkinson's Disease: A randomized controlled trial. Am J Med. 1994;97:429–35. [PubMed: 7977431]
277.
Reynolds H, Wilson-Barnett J, Richardson G. Evaluation of the role of the Parkinson's Disease nurse specialist. Int J Nurs Stud. 2000;37:337–49. [PubMed: 10760541]
278.
Patti F, Reggio A, Nicoleti F. et al. Effects of rehabilitation therapy on parkinsonians' disability and functional independence. J Neuro Rehab. 1996;10:223–31.
279.
Adams S G, Lang A E. Can the Lombard effect be used to improve low voice intensity in Parkinson's Disease? Eur J Disord Commun. 1992;27:121–7. [PubMed: 1446099]
280.
Comella C L, Stebbins G T, Brown-Toms N. et al. Physical therapy and Parkinson's Disease: A controlled clinical trial. Neurology. 1994;44:376–8. [PubMed: 8145901]
281.
DeAngelis E C, Mourao L F, Ferraz H B. et al. Effect of voice rehabilitation on oral communication of Parkinson's Disease patients. Acta Neurol Scand. 1997;96:199–205. [PubMed: 9325469]
282.
Formisano R, Pratesi L, Modarelli F T. et al. Rehabilitation and Parkinson's Disease. Scand J Rehab Met. 1992;24:157–60. [PubMed: 1411361]
283.
Katsikitis M, Pilowsky I. A controlled study of facial mobility treatment in Parkinson's Disease. J Psychosom Res. 1996;40:387–96. [PubMed: 8736419]
284.
Nagaya M, Kachi T, Yamada T. Effect of swallowing training on swallowing disorders in Parkinson's Disease. Scand J Rehab Med. 2000;32:11–5. [PubMed: 10782935]
285.
Pacchetti C, Mancini F, Agliere R. et al. Active music therapy in Parkinson's Disease: An integrative method for motor and emotional rehabilitation. Psychosom Med. 2000;62:386–93. [PubMed: 10845352]
286.
Platz T, Brown R G, Marsden C D. Training improves the speed of aimed movements in Parkinson's Disease. Brain. 1998;121:505–14. [PubMed: 9549526]
287.
Ramig L O, Countryman S, Thompson L L. et al. Comparison of two forms of intensive speech treatment for Parkinson's Disease. J Speech Hear Res. 1995;38:1232–51. [PubMed: 8747817]
288.
Schenckman M, Cutson T M, Kuchibhatla M. et al. Exercise to improve spinal flexibility and function for people with Parkinson's Disease: A randomized, controlled trial. J Am Geriatr Soc. 1998;46:1207–16. [PubMed: 9777901]
289.
Sitzia J, Haddrell V, Rice-Oxley M. Evaluation of a nurse-led multidisciplinary neurological rehabilitation programme using the Nottingham Health Profile. Clin Rehabil. 1998;12:389–94. [PubMed: 9796929]
290.
Thaut M H, McIntosh G C, Rice R R. et al. Rhythmic auditory stimulation in gait training for Parkinson's Disease patients. Mov Disord. 1996;11:193–200. [PubMed: 8684391]
291.
Pacchetti C, Aglieri R, Mancini F. et al. Active music therapy and Parkinson's Disease: Methods. Funcy Neurol. 1998;13:57–67. [PubMed: 9584875]
292.
Smith M E, Ramig L O, Dromey C. et al. Intensive voice treatment in Parkinson's Disease: Laryngostroboscopic findings. J Voice. 1995;9:453–9. [PubMed: 8574314]
293.
de Silva H A R, Khan N L, Wood N W. The genetics of Parkinson's Disease. Curr Opin Genet Dev. 2000;10:292–8. [PubMed: 10826990]
294.
Polymeropoulos M H, Higgins J J, Golbe L I. et al. Mapping of a gene for Parkinson's Disease to chromosome 4q21–q23. Science. 1996;274:1197–8. [PubMed: 8895469]
295.
Gasser T. Is Parkinson's Disease an inherited condition? Adv Neurol. 1999;80:143–52. [PubMed: 10410714]
296.
Tanner C M, Ottman R, Golman S M. et al. Parkinson Disease in twins: an etiologic study. JAMA. 1999;281:341–6. [PubMed: 9929087]
297.
Piccini P, Burn D J, Ceravolo R. et al. The role of inheritance in sporadic Parkinson's Disease: Evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol. 1999;45:577–82. [PubMed: 10319879]
298.
Sveinbjornsdottir S, Hicks A A, Jonsson T. et al. Familial aggregation of Parkinson's Disease in Iceland. N Engl J Med. 2000;343:1767–70. [PubMed: 11114315]
299.
Abbas N, Lucking C B, Ricard S. et al. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. Hum Mol Genet. 1999;8:567–74. [PubMed: 10072423]
300.
Hattori N, Kitada T, Matsumine H. et al. Molecular genetic analysis of a novel parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: Evidence for variable homozygous deletions in the parkin gene in affected individuals. Ann Neurol. 1998;44:935–41. [PubMed: 9851438]
301.
Leroy E, Anastasopoulos D, Konitsiotis S. et al. Deletions in the parkin gene and genetic heterogenity in a Greek family with early onset Parkinson's Disease. Hum Genet. 1998;103:424–7. [PubMed: 9856485]
302.
Lucking C B, Durr A, Bonifati V. et al. Association between early-onset Parkinson's Disease and mutations in the parkin gene. N Engl J Med. 2000;342:1560–7. [PubMed: 10824074]
303.
Hu C J, Sung S M, Liu H S. et al. Polymorphisms of the parkin gene in sporadic Parkinson's Disease among Chinese in Taiwan. Eur Neurol. 2000;44:90–3. [PubMed: 10965160]
304.
Freese A. Restorative gene therapy approaches to Parkinson's Disease. Med Clin North Am. 1999;83:537–48. [PubMed: 10093593]
305.
Latchman D S. Herpes simplex virus vectors for gene therapy in Parkinson's Disease and other diseases of the nervous system. J R Soc Med. 1999;92:566–70. [PMC free article: PMC1297431] [PubMed: 10703493]
306.
Little RJA, Rubin DB. Statistical analysis with missing data. New York: John Wiley & Sons; 1987.

Views

  • PubReader
  • Print View
  • Cite this Page

Other titles in these collections

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...